Ion Beam Applications, SA

Declaration of Voting Results & Voting Rights Announcements • Feb 26, 2015

Press release | Regulated information

IBA – DATA CONCERNING TRANSPARENCY

Louvain-la-Neuve, Belgium, February 26, 2015 - IBA (Ion Beam Applications SA), the global hightech leader in next generation radiation therapy and diagnostics for the treatment of cancer, communicates today the basic and additional data as per Article 15 §1 al.1 of the Transparency Law, following its capital increase (further to exercises of stock options) dated February 26, 2015.

Data concerning transparency Heading II of the law of May 2, 2007 and the Royal Decree of February 14, 2008

Communication of the basic data as per Article 15 §1 al.1 of the Law

• •	Total capital: Total number of securities conferring the voting right: 12 702 489 with VVPR strips)	EUR 40 216 326,69 28 653 520 (of which
•	Total number of voting rights (= the denominator):	28 653 520
•	Total number of securities conferring the voting right, by category:	N/A
•	Total number of voting rights, by category:	N/A
	Communication of the additional data as per Article 15 §1 al.2 of the Law
• •	Total number of convertible bonds conferring the voting right: Total number of rights, materialized or not by certificates, giving the right to subscribe to newly issued securities conferring the voting right	0
	(e.g. warrants):	2 166 370
•	Total number of voting rights which would result from the exercise of
	these conversion or subscription rights:	2 166 370
•	Total number of shares without voting right:	0

Statutory thresholds as per Article 18 of the Law

The applicable thresholds as follows: three percent, five percent, ten percent, fifteen percent and so on by brackets of five percent.

* * * *

About IBA

IBA (Ion Beam Applications SA) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

Press release |

Regulated information

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

IBA employs more than 1,000 people worldwide and is listed on Euronext Brussels, (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB), more information can be found at: www.iba-worldwide.com

For more information, please contact

IBA Caroline Hardy Corporate Legal Counsel +32 10 201 159 caroline.hardy@iba-group.com

Press release | February 26, 2015 2 | 2